117 related articles for article (PubMed ID: 17137636)
1. Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity.
Learn CA; Grossi PM; Schmittling RJ; Xie W; Mitchell DA; Karikari I; Wei Z; Dressman H; Sampson JH
J Neuroimmunol; 2007 Jan; 182(1-2):63-72. PubMed ID: 17137636
[TBL] [Abstract][Full Text] [Related]
2. [CDK1 expression and effects of CDK1 silencing on the malignant phenotype of glioma cells].
Chen H; Huang Q; Zhai DZ; Dong J; Wang AD; Lan Q
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):484-8. PubMed ID: 18069625
[TBL] [Abstract][Full Text] [Related]
3. The chemokine GRO-alpha (CXCL1) confers increased tumorigenicity to glioma cells.
Zhou Y; Zhang J; Liu Q; Bell R; Muruve DA; Forsyth P; Arcellana-Panlilio M; Robbins S; Yong VW
Carcinogenesis; 2005 Dec; 26(12):2058-68. PubMed ID: 16033775
[TBL] [Abstract][Full Text] [Related]
4. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo.
Aulwurm S; Wischhusen J; Friese M; Borst J; Weller M
Int J Cancer; 2006 Apr; 118(7):1728-35. PubMed ID: 16217761
[TBL] [Abstract][Full Text] [Related]
5. Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model.
Ashley DM; Kong FM; Bigner DD; Hale LP
Cancer Res; 1998 Jan; 58(2):302-9. PubMed ID: 9443409
[TBL] [Abstract][Full Text] [Related]
6. Distinct roles of CSF family cytokines in macrophage infiltration and activation in glioma progression and injury response.
Sielska M; Przanowski P; Wylot B; Gabrusiewicz K; Maleszewska M; Kijewska M; Zawadzka M; Kucharska J; Vinnakota K; Kettenmann H; Kotulska K; Grajkowska W; Kaminska B
J Pathol; 2013 Jul; 230(3):310-21. PubMed ID: 23520016
[TBL] [Abstract][Full Text] [Related]
7. lacZ-neoR transfected glioma cells in syngeneic rats: growth pattern and characterization of the host immune response against cells transplanted inside and outside the CNS.
Visted T; Thorsen J; Thorsen F; Read TA; Ulvestad E; Engebraaten O; Sorensen D; Ylä-Herttuala S; Tyynela K; Rucklidge G; Edvardsen K; Bjerkvig R; Lund-Johansen M
Int J Cancer; 2000 Jan; 85(2):228-35. PubMed ID: 10629082
[TBL] [Abstract][Full Text] [Related]
8. Absence of p53 autoantibodies in sera from glioma patients.
Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
[TBL] [Abstract][Full Text] [Related]
9. Progression from low- to high-grade in a glioblastoma model reveals the pivotal role of immunoediting.
Appolloni I; Alessandrini F; Ceresa D; Marubbi D; Gambini E; Reverberi D; Loiacono F; Malatesta P
Cancer Lett; 2019 Feb; 442():213-221. PubMed ID: 30312732
[TBL] [Abstract][Full Text] [Related]
10. Orthotopic transplantation of v-src-expressing glioma cell lines into immunocompetent mice: establishment of a new transplantable in vivo model for malignant glioma.
Smilowitz HM; Weissenberger J; Weis J; Brown JD; O'Neill RJ; Laissue JA
J Neurosurg; 2007 Apr; 106(4):652-9. PubMed ID: 17432718
[TBL] [Abstract][Full Text] [Related]
11. Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells.
Clark AJ; Safaee M; Oh T; Ivan ME; Parimi V; Hashizume R; Ozawa T; James CD; Bloch O; Parsa AT
J Transl Med; 2014 Dec; 12():345. PubMed ID: 25464980
[TBL] [Abstract][Full Text] [Related]
12. Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo.
Huang ZY; Baldwin RL; Hedrick NM; Gutmann DH
Oncogene; 2002 Feb; 21(9):1325-34. PubMed ID: 11857076
[TBL] [Abstract][Full Text] [Related]
13. c-myc oncogene expression and cell proliferation in mixed oligo-astrocytoma.
Banerjee M; Dinda AK; Sinha S; Sarkar C; Mathur M
Int J Cancer; 1996 Mar; 65(6):730-3. PubMed ID: 8631582
[TBL] [Abstract][Full Text] [Related]
14. A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy.
Wakabayashi T; Natsume A; Hashizume Y; Fujii M; Mizuno M; Yoshida J
J Gene Med; 2008 Apr; 10(4):329-39. PubMed ID: 18220319
[TBL] [Abstract][Full Text] [Related]
15. GDF-15 contributes to proliferation and immune escape of malignant gliomas.
Roth P; Junker M; Tritschler I; Mittelbronn M; Dombrowski Y; Breit SN; Tabatabai G; Wick W; Weller M; Wischhusen J
Clin Cancer Res; 2010 Aug; 16(15):3851-9. PubMed ID: 20534737
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion.
Sampson JH; Ashley DM; Archer GE; Fuchs HE; Dranoff G; Hale LP; Bigner DD
Neurosurgery; 1997 Dec; 41(6):1365-72; discussion 1372-3. PubMed ID: 9402588
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated gene transfer of B7.1 induces immunological anti-tumor effects in a murine brain tumor.
Morioka J; Kajiwara K; Yoshikawa K; Ideguchi M; Uchida T; Ohmoto Y; Suzuki M
J Neurooncol; 2002 Oct; 60(1):13-23. PubMed ID: 12416541
[TBL] [Abstract][Full Text] [Related]
18. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
19. Glioma escape signature and clonal development under immune pressure.
Maire CL; Mohme M; Bockmayr M; Fita KD; Riecken K; Börnigen D; Alawi M; Failla A; Kolbe K; Zapf S; Holz M; Neumann K; Dührsen L; Lange T; Fehse B; Westphal M; Lamszus K
J Clin Invest; 2020 Oct; 130(10):5257-5271. PubMed ID: 32603315
[TBL] [Abstract][Full Text] [Related]
20. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.
Sampson JH; Choi BD; Sanchez-Perez L; Suryadevara CM; Snyder DJ; Flores CT; Schmittling RJ; Nair SK; Reap EA; Norberg PK; Herndon JE; Kuan CT; Morgan RA; Rosenberg SA; Johnson LA
Clin Cancer Res; 2014 Feb; 20(4):972-84. PubMed ID: 24352643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
